FDA approves Xolair (omalizumab) for adults with nasal polyps - Seite 4

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Xolair Full Prescribing Information. Genentech, Inc.; November 2020.
[2] Data on file. Genentech, Inc.
[3] United States Census Bureau. QuickFacts. Census Bureau population estimates (2018). Accessed October 2020. https://www.census.gov/quickfacts/fact/table/US/PST045218
[4] Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4(4):565572.
[5] Mayo Clinic. Nasal polyps. Accessed October 2020. https://www.mayoclinic.org/diseases-conditions/nasal-polyps/symptoms-causes/syc-20351888.
[6] Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials. J Allergy and Clin Immunol. 2020; 146(3):595-605. doi: 10.1016/j.jaci.2020.05.032

Roche Group Media Relations
Phone: [phone] / e-mail: [e-mail]

Dr. Nicolas Dunant Phone: [phone]	Patrick Barth Phone: [phone]
Dr. Daniel Grotzky Phone: [phone]	Karsten Kleine Phone: [phone]
Nina Mählitz Phone: [phone]	Nathalie Meetz Phone: [phone]
Dr. Barbara von Schnurbein